Assetmark Inc. Buys 14,341 Shares of Amgen Inc. $AMGN

Key Points

• Assetmark Inc. increased its stake in Amgen by 6.7% in Q4, buying 14,341 shares to hold 228,134 shares worth $74.67 million.
• Analysts have raised price targets (notably Argus and UBS to $400), but the MarketBeat consensus remains a Hold with a $356.24 price target.
• Amgen beat quarterly EPS and revenue, set FY2026 guidance of 21.600–23.000 EPS, and announced a quarterly dividend of $2.52 ($10.08 annual, ~2.9% yield).

Assetmark Inc. grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 6.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 228,134 shares of the medical research company's stock after buying an additional 14,341 shares during the period. Assetmark Inc.'s holdings in Amgen were worth $74,670,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Intelligence Driven Advisers LLC bought a new position in Amgen during the fourth quarter worth about $218,000. Blue Fin Capital Inc. boosted its holdings in Amgen by 24.8% during the fourth quarter. Blue Fin Capital Inc. now owns 7,444 shares of the medical research company's stock worth $2,437,000 after buying an additional 1,477 shares during the last quarter. Ball & Co Wealth Management Inc. boosted its holdings in Amgen by 0.4% during the fourth quarter. Ball & Co Wealth Management Inc. now owns 14,160 shares of the medical research company's stock worth $4,634,000 after buying an additional 58 shares during the last quarter. Webster Bank N. A. boosted its holdings in Amgen by 1.3% during the fourth quarter. Webster Bank N. A. now owns 3,958 shares of the medical research company's stock worth $1,295,000 after buying an additional 51 shares during the last quarter. Finally, Eagle Bay Advisors LLC boosted its holdings in Amgen by 3.9% during the fourth quarter. Eagle Bay Advisors LLC now owns 1,114 shares of the medical research company's stock worth $365,000 after buying an additional 42 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on AMGN shares. Citigroup raised their target price on Amgen from $315.00 to $345.00 and gave the stock a "neutral" rating in a report on Wednesday, February 4th. Argus raised their target price on Amgen from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Friday, February 6th. Wells Fargo & Company lifted their price objective on Amgen from $375.00 to $390.00 and gave the company an "equal weight" rating in a report on Thursday, March 19th. Weiss Ratings reiterated a "buy (b)" rating on shares of Amgen in a report on Monday, December 29th. Finally, UBS Group lifted their price objective on Amgen from $390.00 to $400.00 and gave the company a "buy" rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $356.24.

Amgen Trading Down 0.3%

NASDAQ:AMGN opened at $349.82 on Tuesday. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The stock has a market capitalization of $188.79 billion, a PE ratio of 24.58, a price-to-earnings-growth ratio of 3.30 and a beta of 0.47. The business's 50-day simple moving average is $363.97 and its 200-day simple moving average is $336.03.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion for the quarter, compared to analysts' expectations of $9.46 billion. During the same quarter in the previous year, the business posted $5.31 EPS. Amgen's revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's dividend payout ratio (DPR) is currently 70.84%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.